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Abstract 
 
Active pharmaceutical ingredients (APIs) are entering the environment through 
various pathways and emissions of effluents from pharmaceutical production plants 
are one such source. The production process of a pharmaceutical for the treatment 
of stomach ulcers manufactured at a pharmaceutical production plant in Ireland was 
studied. Data detailing mass flow quantities and compositions were compiled. This 
occurred over a 6 week period following a two week plant shutdown. A computer 
software programme, SuperPro Designer v 5.0, was used to estimate the efficiency 
of the production process, mass flows in waste streams and process streams. Several 
assumptions were made in modelling the actual process including the percentage 
purity of the raw material, the percentage intermediate formation, the percentage 
product formation and the percentage losses during product purification. In order to 
compare predicted and actual concentrations, an LC-ESI-MS/MS method was 
developed to detect the raw material and product in wastewater. A sample point 
where water from the process collects and a sample point prior to the wastewater 
treatment were used. Concentrations in the mg/L range were detected. Mass 
balances of process streams in the pharmaceutical production facility were used to 
estimate the quantities of the raw material and product lost to the waste streams 
which were then compared with the model created using SuperPro Designer v5.0. 
The model was useful in predicting losses of both raw material and product and 
actual wastewater analysis confirms this. Sampling points at each centrifuge in the 
plant would allow the losses to be more accurately quantified. 
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Chapter 1 
Introduction 
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1.1 Presence of pharmaceuticals in the environment 
 
It is well documented that there are detectable quantities of pollutants, 
including pharmaceuticals in the aquatic environment (Glassmeyer et al., 2009, 
Heberer, 2002, Hirsh et al., 1999). Pharmaceutical and Personal Care Products 
(PPCP) are contaminants in the environment which have traditionally not been 
monitored (Aga, 2008). They have the potential for adverse health effects, 
especially endocrine disrupting compounds (Bolong et al., 2009). There has 
been a global detection of pharmaceuticals in environmental samples as a 
result of improved analytical capabilities and detailed field surveys (Focazio et 
al., 2008, Webb, 2003, and Daughton, 2001,).  Methods of detection for these 
micro pollutants have improved with the advent of liquid chromatography 
coupled with tandem mass spectrometry and there has been a significant 
increase in reporting the presence of PPCPs in the environment in the literature 
(Aga, 2008).  
 
The high polarity and low volatility of most pharmaceuticals means that they 
are likely to remain in the aquatic environment (Van der Voet, et al., 2004). Six 
of the main environmental journals have witnessed a six fold increase in 
publications regarding the fate of pharmaceuticals in the environment (Aga, 
2008). Many pharmaceuticals are unlikely to be a risk to the aquatic 
environment because of low concentrations combined with low toxicity but 
other pharmaceuticals such as natural and synthetic sex hormones have been 
shown to pose considerable risks (Bolong et al., 2009). New pharmaceuticals 
may be more persistent in the environment as they are designed to withstand 
degradation. 
 
1.2 Entry to the environment 
 
APIs enter the environment via a variety of pathways, including discharge of 
raw and treated sewage. This occurs by flushing unwanted pharmaceuticals 
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down the toilet/sink or by the presence of unmetabolised compounds excreted 
in faeces and urine (Daughton and Ruhoy 2008). The quantity of publications 
on the fate of APIs in the environment - such as sorption and mobility in soil 
(Lucas and Jones 2009), removal through tertiary treatments (Muñoz et al., 
2009) (Klavarioti, et al., 2009), biodegradation (Kümmerer et al., 2000), and 
photodegradation (Tixier et al., 2003) - indicates the importance of research in 
this field. Secondary treatment of wastewaters is generally ineffective at 
degrading pharmaceuticals (Klavarioti et al., 2009). 
 
The reduction of pharmaceuticals entering the environment may be a more 
important and more effective strategy of removal than attempting to eliminate 
them once in the environment (Ruhoy and Daughton, 2008). Some 
pharmaceuticals are persistent even after wastewater treatment, such as 
gemfibrozil and carbamazepine (Lacey et al., 2008). The pharmaceutical 
industry is both directly and indirectly responsible for the presence of these 
compounds and little has been done to reduce the quantity of pharmaceuticals 
released (Khetan and Collins, 2007). Although pharmaceuticals originate at 
manufacturing plants, little attention has been given to their wastewater 
effluents (Klavarioti et al., 2009). With advances in medical technology and 
growing healthcare spending, the consumption and usage of pharmaceuticals is 
expected to expand as new drugs enter the market and thereby increasing 
pharmaceutical loading on the environment. 
 
There are several reasons for a pharmaceutical plant to reduce the quantities 
of APIs in effluent, including: (i) reduction of the environmental impact, (ii) 
improved public perception of the industry and (iii) to avoid large fines 
imposed by regulatory bodies. The recovery of high value products should be 
part of the production process or at the latest, the purification step. Recovery 
of product should not occur after purification or polishing steps. Legislation is a 
key driver in the reduction of pollution from the pharmaceutical industry and it 
is becoming more stringent as analytical techniques improve (Bolong et al., 
2009). Legislation regarding water quality in the United States, Europe and 
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specifically Ireland is discussed, with the European Water Framework Directive 
(WFD) owing to the tightest regulation.  
 
Recovering APIs from process streams with more efficiency will mean that less 
APIs will be present in the waste streams.  Methods of recovery for an API are 
dependent on several factors including molecular weight, compound 
classification (e.g. protein, small molecule, antibiotic etc.) and cost. 
Chromatography and membrane technology are the main separation 
techniques employed in the pharmaceutical industry (Bolong et al., 2009, Van 
den Heuvel, 2009, Sofer, 1995). For the small molecule pharmaceutical 
industry, downstream processing usually entails filtration technology to 
remove impurities followed by crystallisation steps.  
 
1.3 Treatment Options 
 
Several technologies are available to degrade pharmaceutical residues in the 
municipal wastewater area, including conventional Activated Sludge (AS) 
plants, Activated Carbon (AC), (Watkinson   et al., 2007), Biofilm Reactors 
(BFRs), Sequencing Batch Reactors (SBRs) (Mohan et al., 2006), Membrane 
Bioreactors (MBRs) (Radjenović et al., 2009) and Upflow Anaerobic  Biofilter 
Processes (UABP)(Chen et al., 1994). These technologies have been shown to 
remove pharmaceuticals of certain classes more efficiently than others. 
Advanced oxidation processes for the removal of pharmaceuticals, though 
effective, are expected to be an expensive endeavour for municipal 
wastewater. As initial concentrations of APIs are very low the treatment cost 
per unit mass may be excessive and therefore AOPs are more suited to 
industrial effluents (Klavarioti et al., 2009). The long-term impact of low 
concentrations of APIs on both the environment and human health is still 
unknown (Crane et al., 2006). 
 
Due to the high concentration of pollutants in industrial effluents, recovery of 
solvents, products and raw materials may be of more benefit than treatment, 
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as it increases the efficiency of the process.  Municipal wastewaters have been 
shown to have pharmaceuticals at concentrations of ng/L, whereas the 
effluents of some hospitals and pharmaceutical plants are much higher, in the 
mg/L range (Klavarioti et al., 2009). In most cases of pharmaceutical effluent, 
specific quantities of pharmaceuticals are either not monitored or are not 
publicised. Chemical Oxygen Demand (COD) of streams are reported for 
pharmaceutical industrial effluent and can be in the region of 670-2700mg/L 
(Klavarioti, 2009, Xing et al,. 2006, Hofl et al., 1997). Introduction of regulations 
to reduce the entry of API’s to the environment via production plants is the 
only feasible option for rapid development of technology (Linninger et al., 
2001). There has been a lack of economic incentives to develop “waste-free” 
processes in the pharmaceutical manufacturing industry (Garcia   et al., 2004) 
and practices aimed at water usage reduction were rarely employed (Garcia   et 
al., 2008). The potential risks associated with releases of pharmaceuticals into 
the environment have become an increasingly important issue for 
environmental regulators and the pharmaceutical industry (Crane, et al., 2006).  
1.4 Legislation 
 
Chemical synthesis has traditionally been at the core of pharmaceutical 
production. Improvements in pharmaceutical production facilities have come 
about due to economic incentives and tighter regulations. Legislation has had a 
major impact on the composition of effluent from pharmaceutical facilities as 
demonstrated in the Astellas 2008 Annual Environmental Report for the EPA.  
Improvements in purification technology have undoubtedly been attributed to 
demands from both customers of APIs and regulatory bodies (Févotte, 2007).  
 
The potential risks associated with the release of pharmaceuticals into the 
environment have become an increasingly important issue for environmental 
regulators and the pharmaceutical industry (Crane et al., 2006). Little has been 
done to reduce the quantity of pharmaceuticals released to the environment 
(Khetan and Collins, 2007). Only in 2007, in the United States, the first federal 
recommendations for proper disposal of expired or unused pharmaceuticals 
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were introduced. While discouraging flushing of pharmaceuticals, it 
recommended using State and local collection programs or disposing to rubbish 
bins. The latter disposal method is only to be taken when no collection 
program is available.  Prior to this, it had been recommended to dispose of 
drugs by flushing down the toilet (Glassmeyer, et al., 2009).  
 
A lack of awareness regarding contamination of the environment by 
pharmaceuticals has been highlighted in a survey of residents in Southern 
California. Less than half of respondents were aware that pharmaceuticals 
compounds were present in treated wastewater (Kotchen, et al., 2009). Nearly 
half (49%) used a rubbish bin to dispose of unused pharmaceuticals and 28% 
used a toilet/sink, whereas 10.6% returned the unused drugs to a pharmacy or 
hazardous waste centre. A survey conducted in the United Kingdom reported a 
similar disposal rate to landfill, but only 11% said they flushed them down the 
toilet with 21.8% returning to the pharmacy (Bound and Voulvoulis, 2005). 
Minimising the disposal pathway of pharmaceuticals could be more effective 
and less costly than extensive Wastewater Treatment Plant (WWTP) 
retrofitting. 
 
In Ireland, a pharmacist “may accept the return of a medicinal product” (S.I. 
No. 488 of 2008), but no regulations regarding the disposal by consumers have 
yet been made.  Similarly, in the United Kingdom discarded pharmaceuticals 
are defined as clinical waste and are controlled by the Special Waste 
Regulations 1996 (HMSO, 1996). This legislation requires the pharmaceuticals 
to be disposed of in designated hazardous waste landfill sites or to be 
incinerated. However, once obtained by a member of the public, these types of 
waste are regarded as household waste and are not subject to any controls 
(Bound and Voulvoulis, 2005). New pharmaceuticals designed to withstand 
degradation and with more specific biological targets, may become more 
persistent in the environment. It is suggested that pharmaceutical producers 
should highlight environmental precaution when designing new drugs 
(Gunnarsson and Wennmalm, 2008). 
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In the United States, the Clean Water Act (1977) was brought into law in order 
to restore and improve the quality of all water sources. The aim was to 
eliminate the discharge of pollutants to navigable waters by 1985. To achieve 
this, federal funding was committed to construct publicly owned wastewater 
treatment works to develop technology which could eliminate pollutants 
before entering surface waters (Federal Water Pollution Control Act, 1972). No 
references to pharmaceuticals are made in this legislation. The paucity of 
regulation regarding pharmaceuticals at the time, compared with today, is 
indicative of the advances made by the regulatory authorities. The Oslo 
Convention was commissioned in 1972 to protect the marine environment of 
the North-East Atlantic. The Paris Convention of 1974 broadened this scope to 
cover land-based sources and off-shore industry. This was up-dated and 
extended resulting in a new annex, the 1992 OSPAR Convention 
(www.ospar.org). In 1989, the Irish Environmental Protection Agency carried 
out the first systematic nationwide assessment of drinking water quality. A 
total of fifty three bacteriological, chemical and physical parameters were 
examined (Flanagan, 1991). The quality of drinking water was generally good, 
with private group schemes showing breaches in microbiological 
contamination. This is reflected in a subsequent report (Clabby et al., 2008).  
 
A less-investigated path of entry of pharmaceuticals to the environment is from 
the production processes. Diminution of released APIs in waste streams may be 
encouraged by a change in the regulatory environment (García et al, 2008). 
Residues of pharmaceuticals in aquatic systems are not yet included in regular 
monitoring programs. This is attributed to the high cost of equipment 
(Buchberger, 2007). The persistence and occurrence of endocrine disrupting 
compounds is attributed to the “nonexistence of limiting regulations, especially 
for new compounds, by-products, pharmaceuticals and PPCPs as related to the 
water and wastewater treatment industry” (Bolong et al., 2009). The European 
Water Framework Directive (WFD) set up objectives to achieve “good water 
status” for all European waters by 2015. In the WFD, a clear structure has been 
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set out to enable these objectives (Loos, et al., 2008). Not all Irish water meets 
this “good status” (Clabby et al., 2008). Nitrogen and phosphorous are the 
primary pollutants and enter surface waters from agriculture, sewage and 
detergents, amongst others. In the WFD, no specific regulations regarding 
pharmaceutical contamination of either industrial or municipal wastewaters 
are set out. However, the WFD includes 33 priority chemicals and 8 pollutants 
that will be subject to cessation or phasing out over the next 6 years (Official 
Journal L 327/22, 2000). The production of a number of these has been 
prohibited in a number of countries, including Ireland. Separate to that, the 
European Reach legislation (Official Journal L 396/1, 2006) seeks to provide a 
legal framework for dealing with chemicals ensuring a high level of health and 
environmental protection (Hogenboom, et al., 2009). The objective of the 
Reach legislation is the classification of chemicals and compilation of data such 
as environmental fate, physical and chemical properties and physicochemical 
properties, toxicological data, compositional data, chemical identity, volume of 
production, uses and exposure data (Official Journal L 396/1, 2006). Even 
though Astellas products are currently not on the priority list, it is possible that 
they may be included in time to come.  
 
According to the Food and Drug Administration (FDA), the Good Manufacturing 
Practice (GMP) guidance for manufacturing and processing of APIs requires 
material accountability and traceability, as well as mass-balancing of all 
reactions during manufacturing. Process analytical technologies (PAT) were 
introduced in late 2002 by the FDA, to allow the introduction of new 
technologies which analyse and control manufacturing during processing.  The 
analysis of raw and in-process materials may reduce risks to quality and 
regulatory concerns while improving efficiency of the process. This may also 
reduce the quantity of pharmaceuticals entering the environment. In 
pharmaceutical plants, the actual yields are compared with expected yields at 
designated steps in the production process. Expected yields with appropriate 
ranges are established and deviations from critical process steps should be 
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investigated (FDA, 2001). These measures are gradually making pharmaceutical 
manufacturers aware of their environmental impact.  
 
Integrated pollution prevention control licences (IPPC) are required by 
industries which discharge pollution caused by certain substances into the 
aquatic community (Official Journal L 24/8, 2008). European law requires 
enforcement of these Directives. IPPC licences require production facilities to 
review the way in which they conduct their business, to innovate where 
necessary and to decouple production from environmental pollution. The 
Office of Environmental Enforcement (OEE) enforces these regulations. In the 
United States, no maximum limit of PPCPs in either drinking or natural waters 
has been regulated. However, when environmental concentrations of 
pharmaceuticals exceed 1µg/L, the Food and Drug Administration does require 
ecological testing and evaluation of pharmaceuticals (Bolong, et al., 2009) 
1.5 Link between downstream processing and legislation 
 
Legislative efforts to reduce the environmental impact of pharmaceutical 
companies have shifted the mindset of the industry to adopt greener 
technologies. In 2005, the American Chemical Society (ACS), Green Chemistry 
Institute (GCI) and other leading global pharmaceutical corporations developed 
the ACS GCI Pharmaceutical Roundtable to encourage the use of green 
chemistry in drug discovery and production of active pharmaceutical 
ingredients (Constable et al., 2007). Solvent-less cleaning and replacement of 
dipolar aprotic solvents were discussed, amongst others.  This type of 
production may very well reduce the quantities of pollutants entering the 
environment, but for validated methods, this may not be feasible. Therefore, 
other means of pollution prevention are necessary. Pharmaceutical waste 
streams typically have high COD concentrations, compared with municipal 
waste water (Klavarioti et al., 2009). There is a general paucity of literature 
concerned with recovery of pharmaceutical products from industrial 
wastewater, most of which deal with the recovery of proteins by means of 
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membrane technology (Oatley et al., 2005). One would speculate the reason 
for the lack of pharmaceutical recovery is propriety or that there is currently 
very little research being carried out in this area, or both. Whichever the case 
may be, there is sufficient evidence from other sectors that technologies exist 
for the recovery of pharmaceutical from wastewater, possibly by membrane 
technology (He et al., 2004). There are several publications on recovery of 
waste by-products from wastewaters, including heavy metals from the 
wastewater of the electrical industry (Cui and Zhang, 2008) and dyes from the 
textile industry (Muthuraman et al., 2009, Mittal et al., 2006). These 
technologies may be applied to the pharmaceutical industry, in conjunction 
with wastewater treatment (as mentioned in section 1.3), to ameliorate the 
quality of water in effluents of plants.  
 
1.6 Modelling 
 
The operation of pharmaceutical plants must be understood in order to predict 
the emission points of pharmaceutical contaminants. One needs to apply the 
conservation of mass when searching for pollutants coming from 
pharmaceutical plants. Mass balancing is a fundamental step involved in 
theoretical analysis. To understand the performance of a system, two methods 
of analysis are possible: empirical investigation and mathematical modelling. 
The former would require several experiments to be performed. This may not 
provide sufficient information, as correlations to cover every process 
eventuality are necessary to do this (Ingham et al., 1994). There are several 
categories of models but they can generally be separated into two types: 
steady-state and dynamic models (Tirronen and Salmi 2003). For steady-state 
models, the rate of change of mass is zero and therefore there is no 
accumulation in the system (Ingham et al., 1994). Continuous production 
processes are steady-state models, whereas batch and semi-batch systems are 
dynamic models, as the rate of change is a non-zero value (Harrison et al., 
2003). The level of detail in any model depends on its purpose – a basic model 
is produced and layers of complexity are added until the model meets its 
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requirements (Gosling, 2005). Mathematical modelling attempts to describe 
both actual and probable behaviour in a process (Dunn et al., 2000). 
 
Pharmaceutical plants are usually complex dynamic systems designed to 
optimally perform at minimum cost. The traditional sequential procedure 
followed to design pharmaceutical plants involves the development of a 
flexibility analysis, commonly based on steady-state calculations and 
knowledge gained from similar production processes (Ricardez Sandoval et al., 
2008). The use of dynamic models, as opposed to steady-state models for 
pharmaceutical plant analysis, has only recently been made possible through 
the use of powerful computer simulation software (Ingham et al., 2007). 
Mathematical models can be used to simulate, analyse and optimise the 
processes involved in chemical and pharmaceutical production (Tan et al., 
2004). Optimisation includes direct maximisation of product yields while 
increasing efficiency of the process. The term also accounts for the prediction 
of API loss and the facilitation of their recovery from waste streams (Bowen 
and Wellfoot, 2002). 
 
Models can be used to identify where and when measurable concentrations of 
pharmaceuticals will occur in the environment even when the actual 
concentrations are in the ng/L range and are often associated with complex 
matrices (sediment, soil, etc.) (Jørgensen and Halling-Sørensen, 2000). Models 
can also be used, for example, to predict the degradation of pharmaceuticals in 
waste treatment processes (Seth   et al., 2007). Comparison of predictions with 
actual measurement can serve to highlight inadequacies of the models and 
lead to their refinement. Models may start from simple mass balances and can 
be progressively refined. 
 
The purpose of creating a model is to simulate, as accurately as possible, what 
is happening in a system. Chemical and pharmaceutical companies use a range 
of software tools to analyse complete processes. Computer programs use 
several mass balance equations and allow them to be solved rapidly. These 
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tools allow the generation of process flow diagrams, mass and energy 
balancing as well as estimation of operating costs.  
 
The modeller must identify important variables and their effect on the system. 
Understanding critical parameters and generating mathematical equations 
gives the modeller further insight to the system. Once the model has been 
formulated, it can be solved and then compared with experimental data. 
Deviations from actual data may be used to further redefine or refine the 
model until good agreement between it and experimental data is achieved 
(Dunn et al., 2000). It is important to calibrate and validate the applied models 
against real data. 
 
1.7 Research overview 
 
Pharmaceuticals which have not been completely removed by wastewater 
treatment have been found to be present in surface waters (Cooper et al., 
2008, Ternes, 1998). Famotidine - a pharmaceutical produced by Astellas Ltd., 
Mulhuddart, Co. Dublin - is indicated for active and maintenance therapy of 
various types of ulcers and hypersecretory conditions (Fahmy and Kassem, 
2008). Famotidine is a histamine H2-receptor antagonist for treatment of ulcers 
in the stomach and intestine, its molecular structure is presented in Figure 1.1 
(Helali et al., 2008). Its mechanism of action selectively antagonises histamine 
H2 receptors inhibiting stomach acid production. 
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Figure 1.1 Famotidine structure. 
 
Famotidine’s pharmacological effects, site of action, and clinical uses are the 
same as for the other H2-receptor antagonists, but on equimolar bases, 
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famotidine is reported to be about 7.5 and 20 times more potent than 
ranitidine and cimetidine, respectively (Fahmy and Kassem, 2008). 
Famotidine’s potency is of concern when one considers the presence of 
pharmaceuticals in surface waters and their impact on the aquatic organisms 
(Daughton and Ruhoy, 2008). Little information is known about the raw 
material TPN (see Figure 1.2).  The pharmaceutical industry is becoming more 
cognisant of its impact on the environment and has begun to take preventative 
action of pollution reduction. Astellas has collaborated with DCU to assess the 
wastewater on site with a view to identifying further means for improving the 
production process efficiency and reducing their environmental impact. One 
way to achieve this goal is to model a production plant’s chemical processes 
and conduct mass balances which may show where product is unaccounted for 
and highlight stages in these processes which can be optimised to reduce these 
losses. SuperPro Designer v5.1®, a software package that specialises in 
modelling chemical unit operations and scheduling conflicts, is widely used 
within this industry and was chosen to model the production of famotidine. 
The parameters which can be modelled using SuperPro Designer include mass 
transfer, energy usage, plant economics and employee costs. In the 
development phase of a SuperPro Designer model, the process for the selected 
chemical route is laid out on a flow sheet. Mass balances, preliminary energy 
balances and basic recipes are generated for the process. The physical 
properties for pure compounds and mixtures are acquired from literature and 
data banks or they are estimated with appropriate physical property data. The 
scheduling of the unit operations are set out and gantt charts may be 
generated to characterise process bottlenecks.  For the scope of this research, 
energy balancing and plant economics were omitted and only mass transfer 
was examined. 
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Figure 1.2 TPN Structure. 
 
Two polymorphs of famotidine are produced at the plant at Astellas Ltd. These 
are A-form and B-form crystals. For HPLC methods of detection, A-form 
polymorph was supplied by Astellas. Scanning Electron Microscope images of 
TPN and famotidine are seen in Figure 1.3.   
 
     
Figure 1.3 scanning electron microscope images of (i) TPN particles and (ii) A-
form famotidine molecules. 
 
During the purification process, both polymorphs are used at different stages 
to seed dissolved famotidine solutions and crystallise the product. The filter 
mesh-sizes in the basket centrifuges are different to increase the purification 
process efficiency. For this reason two types of crystal are used. In the final 
purification stage the production process splits to either the A-form route or 
the B-form route. The polymorphs are different sized crystals and are sold to 
two separate markets. A schematic of the production process is shown in 
Figure 1.4. 
 
The objective of the project was to model the production of famotidine using 
SuperPro Designer in order to predict where losses of raw material and product 
may occur. This was to be then corroborated using experimental analysis of 
real process wastewaters from Astellas. 
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Chapter 2 
Materials and methods 
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2.1 Materials 
 
Methanol and water were purchased from Fisher Scientific Ltd., Dublin, Ireland 
and were of LC-MS grade. Phosphoric acid solution (85%) and hydrochloric acid 
solution (≥37%), along with dichlorodimethylsilane and toluene, both HPLC 
grade, were purchased from Sigma-Aldrich, Dublin, Ireland. Formic acid (≥98%) 
and ammonium hydroxide solution (25%) were purchased from Fluka, Buchs, 
Switzerland. The analytes for investigation were famotidine (3-(((2-
((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio) -N- (aminosulfonyl) 
propanimidamide) (≥99%) and TPN (3-(2-Guanidino-thiazol-4-yl-methylthio)-
propionitrile) (≥99%) and were obtained from Astellas Pharma Co. Ltd., Dublin, 
Ireland. A reverse phase Luna-pentaflourophenyl propyl (PFP) column 3.5μm 
particle, 150 x 4.6mm was used for standard HPLC analysis and a Luna PFP 
3.5μm particle, 150 x 2.1mm was used for LC-MS analysis and were purchased 
from Phenomenex Inc., United Kingdom. Strata-X-C (3ml/200mg) solid phase 
extraction cartridges were also purchased from Phenomenex Inc., United 
Kingdom. 
 
1000mg/L stock solutions of each analyte were prepared in methanol and 
stored at 4°C. Working standards were prepared by diluting these stock 
solutions using mobile phase.  
 
HPLC vials (APEX Scientific, Co. Kildare, Ireland) and centrifuge vials (Fisher 
Scientific Ltd.) were made of amber glass to prevent degradation of analytes by 
light. All solvents used in HPLC analysis were filtered through Pall nylon filters 
(0.2μm pore size, 47mm diameter) and degassed by sonication for 30 min prior 
to use. Whatmann no 3. glass-fibre filters were used for sample filtration. 
SuperPro Designer V 5.1® (Intelligen, Boston, MA, USA) was used to model the 
production process of famotidine.  
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2.2 Glassware preparation 
 
All glassware used was silanised by rinsing thoroughly with a 10% (v/v) solution 
of dichlorodimethylsilane in toluene followed by two toluene rinses and then 
two methanol rinses. This was to prevent any pharmaceutical residue 
adsorbing to the glassware.  
 
2.3 Method Development 
Famotidine and TPN were expected to be present in wastewater at the Astellas 
production plant. A quantifiable method of detection for famotidine and TPN 
was developed to validate the model. High performance liquid chromatography 
(HPLC) was used to detect both analytes. This method was then transferred to 
a liquid chromatography mass spectrometer (LC-MS/MS) to measure the 
analytes quantitatively and qualitatively. Other compounds which elute from 
the HPLC column at the same time as famotidine and TPN were present in the 
wastewater as other peaks were observed in chromatograms. The mass 
spectrometer first positively ionises famotidine and TPN. The ions are isolated 
in an ion trap and are fragmented to their respective daughter ions (see Figure 
2.2). Famotidine is always fragmented to an ion of 259m/z and TPN to 155m/z. 
Therefore LC-MS/MS is a confirmation step as well as a quantitative method. A 
solid phase extraction (SPE) method was developed for both analytes but the 
concentration of famotidine in actual wastewater was quantifiable without 
pre-concentration. 
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Figure 2.1 Method development flow chart. 
 
An Agilent 1100 LC system (Agilent Technologies, Palo Alto, CA, USA) with a UV-
Vis detector was used for the development of the HPLC method. Separation of 
the analytes was performed with a 3.5μm particle, 150 x 4.6mm, Luna PFP 
reverse phase column (Phenomenex, UK). Varying ratios of methanol and 
water with formic acid (pH 2.7) and acetonitrile and water with formic acid (pH 
2.9) allowed the identification of the optimum mobile phase for separation of 
both analytes. It was determined that a mobile phase composition of 23% 
methanol / water with 0.1% formic acid (pH 2.7) was the optimum. After 
running the sample, a gradient mobile phase with 90% methanol/water v/v 
with 0.1% formic acid was used to remove unwanted organic contaminants 
from the column which may be present in the wastewater (see Table 2.1).  
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Table 2.1 HPLC gradient timetable. A: 23:77 v/v (methanol/water) with 0.1% 
formic acid. B: 90:10 v/v (methanol/water) with 0.1% formic acid. 
Time (mins) 
Mobile phase A 
(%) 
Mobile phase B 
(%) 
0 100 0 
8 100 0 
9 0 100 
15 0 100 
16 100 0 
20 100 0 
 
Samples were injected with 50µL injection volume at a flow rate of 1.0mL/min. 
The optimum wavelength for both analytes (267nm) was determined using UV-
Vis scanning spectroscopy. The optimised method was then transferred to a 
narrower bore 3.5μm particle size, 150 x 2.1mm Luna PFP reverse phase 
column for mass spectrometry application. The flowrate was adjusted to 0.3 
mL/min and the injection volume was reduced to 20μL. A summary of the main 
parameters used are shown in Table 2.2. 
Table 2.2 Parameters of LC for detection of famotidine and TPN 
Mobile phase A 23:77 (v/v %) methanol/water with 0.1% formic acid 
Mobile phase B 90:10 (v/v %) methanol/water with 0.1% formic acid 
Flow-rate 0.3 mL/min 
Wavelength 267 nm 
Column type 3.5μm particle size, 150 x 2.1mm Luna PFP reverse phase column  
Retention time (min) 2.45 for famotidine and 5.8 for TPN 
Injection volume 20 μL 
Run time 20 minutes 
 
2.4 Mass Spectrometer 
A Bruker Daltonics Esquire~LC ion trap MS with an electrospray ionisation 
interface at atmospheric pressure was used for MS analysis. MS conditions 
were optimised separately by direct infusion. Standard solutions (10mg/L) of 
each analyte were directly infused, using a Cole Parmer 74900 series syringe 
pump (Cole Parmer, Vernon Hills, IL, USA), into the mass spectrometer at a 
 31 
flowrate of 300μL/h with a Hamilton 1710N gastight syringe. The analytes were 
monitored in positive mode. The parent ion response for TPN and famotidine 
were 242m/z (M+1) and 338m/z (M+1) respectively.  MS conditions were 
automatically optimised using Bruker Esquire software for each analyte. The 
optimum intensities of each analyte were different for some focusing 
parameters therefore a compromised value was chosen. The precursor peak 
with the greatest intensity was fragmented using tandem MS and the most 
abundant product ion was chosen for monitoring of the tandem MS signal. The 
product ions for TPN and famotidine were 155m/z and 259m/z respectively 
and their likely structures are shown in Figure 2.2 
Table 2.3 Mass spectrometer parameters and values. 
Parameter Default TPN 242m/z 
Famotidine 
338m/z 
Combined 
Method 
Capillary Voltage -4000V -4500V -4254V -4000V 
Endplate Offset -500V -718V -752V -1080.4V 
Skim 1 35V 35.9V 15.0V 25V 
Cap Exit Offset 60V 50V 50V 50V 
Octopole 2.8V 2.77V 2.38V 301V 
Octopole Delta 2.4V 2.39V 2.22V 2.34V 
Trap Drive 55 45.57 33.06 37.2V 
Skim 2 6V 7.62V 5.9V 6.4V 
Octopole RF 150V 103.28V 213.93V 132.0V 
Lens 1 -5V -4.54V -3.66V -3.6V 
Lens 2 -60.98V -64.43V -59.84V -56.4V 
 
 
The completed LC-ESI-MS/MS method for analysis used an Agilent 1100 LC 
system (Agilent Technologies, Palo Alto, CA, USA) coupled to a Bruker Daltonics 
Esquire-LC ion trap MS with an electrospray ionisation interface at atmospheric 
pressure (Bruker Daltonics, Coventry, UK). A Phenomenex narrow bore, 150 x 
2.1mm Luna PFP reversed phase column with 3.5μm particle size was used for 
separation. The pentaflourophenyl propyl coated silica beads have a 
multiplicity of selectivity mechanisms including hydrogen bonding, dipole-
dipole, aromatic and hydrophobic interactions, which make it ideal for 
separation of basic pharmaceuticals. A flowrate of 0.3mL/min and an injection 
volume of 20μL were used. The LC-ESI-MS/MS system was controlled using 
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Agilent Chemstation version A.06.01 and Bruker Daltonics Esquire Control 
version 6.08. Bruker Daltonics data analysis software was used for data 
analysis.  
 
 
Figure 2.2 LC separation of famotidine and TPN and their corresponding 
daughter ions. 
 
2.3 Solid Phase Extraction 
 
Solid phase extraction (SPE) cartridges were used to pre-concentrate samples. 
Phenomenex Strata-X and Strata Screen and Strata X-C were investigated for 
recovery of the analytes. Strata X-C showed best recoveries (>80%). Strata X-C 
cartridges have mixed-mode selectivity which contains a reversed phase mode 
and a strong cation exchanger. As the cartridges are cation exchangers, the 
analyte must be positively charged in order for it to bind to the cartridge. As 
famotidine and TPN are weak bases, they were acidified using 1M phosphoric 
acid. Prior to extraction the solid phase cartridges were washed with three 
column volumes (6mL) of methanol followed by three column volumes of 
TPN 
Fragment 
155 m/z  
N
NH2
S
N
H2N
S N
S
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O
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Famotidine  
Fragment 259 m/z 
N
S
N
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S
N
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water. Deionised water was spiked to a concentration of 40μg/L of each 
analyte and was acidified to pH 2.5 with 20µL of 1M phosphoric acid and 
brought to the mark (25mL) with deionised water. The analytes were passed 
through the solid phase extraction cartridges using vacuum. Cartridges were 
then washed with two column volumes of 0.1% phosphoric acid in water after 
the addition of the sample and dried for 5 minutes under vacuum. The 
cartridges were washed with two column volumes of methanol and eluted with 
5% NH3OH into 20mL amber centrifuge vials. The samples were dried using a 
MiVac Rotavaporator for 5h at 30°C and reconstituted in 1mL of mobile phase 
A.  
 
To calculate the percentage recovery of each analyte, 1mL of working solution 
was added to a 25mL volumetric in triplicate and brought to the mark with 
deionised water, which had been acidified to pH 3 with 0.1% phosphoric acid. 
The analytes were then extracted by solid phase extraction and concentrated 
by a factor of 25. Three cartridges were loaded with acidified deionised water 
as a control, and were spiked with 1mL of working solution, post-extraction. 
These were dried on a MiVac Rotavaporator for 5h at 30°C to calculate any 
losses during drying. All six samples were assayed by LC-MS and compared 
against the working solution of 1mg/L. The concentration recovered was 93% ± 
4%, of the initial concentration.  
 
2.4 Water Sampling 
 
Polypropylene bottles were used for the collection of wastewater samples at 
Astellas Pharma Co. Ltd., Dublin, Ireland and were transferred to amber glass 
bottles off-site. The amber bottles were silanised prior to sampling. Two 
sampling points were identified in the plant and are shown in (see figure 1.4). 
Sampling took place over a 6 week period (5th August 2009 to 16th September 
2009) following a two week shutdown of the plant. Samples from both points 
were collected and transported to the laboratory. The samples were filtered 
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through Whatman glass fibre filters to remove suspended solids and adjusted 
to pH 3 using 5M phosphoric acid and samples were stored at 40C until 
analysed. 
 
2.5 SuperPro Designer V 5.1 
 
SuperPro Designer V 5.1® from Intelligen, Boston, MA, USA was used to model 
the production of famotidine and to estimate quantities of impurities 
produced, specifically, the reaction extent and completions were analysed.  A 
process flow diagram was generated using information obtained about the 
equipment used in Astellas (see figure 1.4). Physical properties of the chemicals 
used in the production of famotidine were obtained from Astellas and were 
inputted to the model. The production of imidate was examined first using 
various permutations of reaction extents between the raw materials. 
Assumptions were made to elucidate what quantity of raw material was 
unreacted or converted to impurities, and what quantity of imidate is produced 
and converted to famotidine. Large amounts of data were generated and those 
which were far outside the actual range observed in Astellas were discarded. 
Several sensitivity analyses were performed on the model. The results from the 
sampling regime were used to corroborate the findings of the model.  
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Chapter 3 
Production process of famotidine in Astellas Ltd., Ireland 
 
 36 
3.1 Step 1 – Synthesis of imidate 
 
420kg of the raw material TPN  are dissolved in 1263L of mixed solvent, 
dioxane/methanol (2:1 v/v), in vessel VE-2100 (see Figure 3.1). TPN is known to 
have an impurity, A-5 (see Appendix A), which constitutes approximately 0 – 
2.5% of TPN. There are eight known impurities which may be formed 
throughout the production process, named A-1 to A-8 and whose IUPAC names 
are listed in Appendix A. After mixing the solution of TPN for three days, HCl 
gas is passed through the solution for 14h to form imidate·HCl. The impurities 
produced at this stage in the process are known to be A-4 and A-3. Methanol 
reacts in a 1:1 reaction with TPN·HCl (see Figure 3.2). 
 
 
Figure 3.1 Formation of the intermediate imidate. 
 
  
 
 37 
 
N
S
N
H2N
H2N S
N
S
N
H2N
H2N S
HN
O
CH3N
HO
CH3+
 
Figure 3.2 Protonation of TPN with HCl allows methanol to react and produce 
imidate·HCl (Astellas). 
 
Imidate·HCl solution is transferred to the next vessel, VE-2200, where the 
hydrochloride molecules are removed and neutralised by 1403kg potassium 
carbonate dissolved in 6947L water (see Figure 3.1). The products of this 
reaction are free-imidate base, carbon dioxide, potassium chloride and water 
(see Figure 3.3).  
 
OHKClOSHCCOCOKHClOSHC 2251592322159 222 +++⇒+•  
Figure 3.3 Imidate neutralisation reaction. 
 
 
The solution is pumped to a basket centrifuge, MA-2200, and undergoes thirty 
cycles of centrifugation washing with 85L water for each cycle. The wastewater 
is then transferred to WWA – a holding tank which contains approximately 
19% solvent and 81% water which subsequently is transferred for on-site 
thermal treatment (Ettarh, 2008).  
 
The water washes remove inorganic compounds such as potassium carbonate 
and potassium chloride which is formed when hydrochloride reacts with 
potassium carbonate. A methanol wash then removes water from the imidate. 
No data regarding the compositions of the filtrate and retentate are available.  
Approximately 510 kg of wet imidate are produced which are equivalent to 455 
kg dry imidate (Astellas Ireland Co. Ltd., 2006). The retentate slurry is 
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transferred to a hopper (VE-2320) in preparation for the next step in the 
process. 
3.2 Step 2 – Synthesis of famotidine 
 
349.9 kg of sulphamide are dissolved in 815L of methanol and 116.3L of 
triethylamine (TEA) in vessel VE-2300/2800. Wet imidate slurry from hopper 
VE-2320 is added to VE-2300/2800 in six aliquots over a period of 48h. Imidate 
and sulphamide react in a 1:1 reaction to form crude famotidine (CFM) and 
methanol (see Figure 3.4). Other compounds that may be produced in this 
reaction are A-7 and A-8, usually about 0.07% to 0.1% of crude famotidine 
yield. The yield of crude famotidine is approximately 74% from TPN. It is 
thought that this low yield is due to imidate degrading to impurities A-4 and A-
7. However, no standard of any impurity (A-1 to A-8) was available to develop 
a method of detection. 
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Figure 3.4 Imidate reacts with sulphamide to form famotidine. 
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Figure 3.5 Vessel VE-2300/2800 is used for the reaction between sulphamide 
and imidate to produce famotidine. 
 
The crude famotidine solution is seeded with 0.5kg of A-form famotidine 
crystals. This slurry is pumped to a centrifuge, MA-2300, and nineteen cycles of 
centrifugation are performed. Approximately 463kg of wet crude famotidine 
are present in the retentate. The dry weight of this is usually 413kg. The filtrate 
contains unreacted sulphamide, dissolved famotidine and impurities A-7 and 
A-8. The filtrate is transferred to a vacuum distillation column for recovering 
sulphamide. Filtrate is stored in a 3000L vessel at ambient temperature, and 
vacuum distillation is performed until a final volume of 750L is reached. 847L 
of ethanol are added and subsequently centrifuged in 9 cycles, washing with 
50L of methanol per cycle. The typical recovery of sulphamide is 124 kg, from 
245 kg initially. The waste methanol in the filtrate is transferred to WWA1 for 
thermal treatment. 
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3.3 Step 3 – Purification of semi-pure famotidine 
 
Crude famotidine is stored in a hopper, VE-2420, until it is transferred to 
VE2400, where it is dissolved in 1308L of 1,1-dimethylformamide (DMF). 43.4L 
of TEA is added, which allows famotidine to crystallise and keep impurities in 
solution, during the seeding step. 1786L of water are added to prevent 
famotidine from re-dissolving, as famotidine is insoluble in water. The vessel is 
seeded with B-form famotidine crystals and famotidine molecules crystallise 
(see Figure 3.6).  
 
 
Figure 3.6 The 1st stage in purification involves crystallisation, centrifugation, 
dissolution and adsorption. 
 
 
The slurry, known at this stage as semi-pure famotidine (SPFM) is pumped to 
centrifuge MA-2400, undergoing 14 cycles of 74L water washes. This water is 
transferred to WWA. The retentate is added to VE-2500, and is dissolved in a 
mixture of 2927L of water, 1915L of ethanol and 107L of acetic acid. Between 
7kg and 30kg of activated carbon are added to the solution. The purpose of 
activated carbon is to remove impurities by adsorption. The quantity of 
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activated carbon is dependent on the amount of A-8 present following QC 
analysis of crude famotidine. The suspension of activated carbon and dissolved 
SPFM is filtered, removing all of the activated carbon. No data regarding the 
quantity of impurities or active pharmaceutical ingredients removed or 
remaining in solution are available. 
3.4 Step 4 – Purification of final product 
 
Depending on the polymorph required, the filtrate from the carbon filter 
containing dissolved SPFM is transferred to either VE-2600 for A-form or VE-
4600 for B-form crystals (see Figure 3.7). 62.6kg of sodium hydroxide 
neutralises the acetic acid. The vessel is seeded with A-form famotidine to 
crystallise pure famotidine (PFM) and 394L of water are added to prevent 
famotidine from dissolving. The slurry is centrifuged for 25 cycles, with 60L of 
water and 30L of ethanol per cycle for A-form.  
 
 
Figure 3.7 The final stage in the purification process of famotidine. 
 
For the B-form route, the centrifuge is larger and 3 cycles of 346L of water and 
172L of ethanol are performed. The retentate is then dried in a rotary dryer for 
24h at less than 35˚C and approximately 385 kg of pure famotidine are 
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recovered. This equates approximately to a 65% yield. A theoretical one 
hundred percent molar stoichiometry of the process was calculated to yield 
587kg of famotidine, if one hundred percent purity and completion of 
reactions are considered.  
 43 
Chapter 4 
Results and Discussion 
 44 
4.1 Experimental results 
 
Famotidine and TPN were detected at two sample points for each day of a six 
week sampling period (see Figure 4.1). The levels ranged from 0.8mg/L to 
16.6mg/L in WWC1 and 0.27mg/L to 5.85mg/L in the pH adjust tank (see Table 
4.1) for famotidine. Values of TPN detected ranged from 0.03mg/L – 0.44mg/L 
in WWC1 and from 0.01mg/L – 0.97mg/L in the pH adjust tank (see Table 4.1). 
For full tables of data see Appendix F. The highest concentration of famotidine 
(16.53 mg/L) was reported in the 4th week post shutdown, on the 2nd 
September in WWC1. This would equate to a mass of 1.653 kg of famotidine 
(see Table 4.2) and corresponds to 0.43% of the total average production of 
385kg, assuming WWC1 was full and has a tank capacity of 100m3. The tank 
capacity is a major assumption. It is not possible to quantify mass flows in the 
pH adjust tank as its capacity is not known and the tank has a weir and 
discharges by overflow on a continuing basis.  
 
Table 4.1 Concentrations of famotidine and TPN in WWC1 and pH adjust tank. 
 
Date 
Conc. famotidine 
WWC1 
(mg/L) (n=2) 
Conc. TPN 
WWC1 
(mg/L) (n=2) 
Conc. Famotidine 
pH adjust (mg/L) 
(n=2) 
Conc. TPN in pH 
adjust (mg/L) 
(n=2) 
05-Aug 2.75 0.04 1.1 <LOQ 
07-Aug 0.8 0.07 1.23 * 
10-Aug 2.15 0.03 1.15 0.01 
12-Aug 3.63 0.29 0.97 0.06 
14-Aug 5.96 0.11 3.1 <LOQ 
19-Aug 1.98 0.44 1.35 0.20 
21-Aug 0.82 0.11 0.49 0.01 
26-Aug 1.2 ** 0.96 0.97 
28-Aug *** *** 0.27 0.85 
01-Sep *** *** 5.85 0.03 
02-Sep 16.53 0.38 3.5 0.05 
03-Sep 11.19 <LOQ 4.79 * 
10-Sep 10.07 0.12 4.83 0.62 
16-Sep 5.31 0.08 2.23 <LOQ 
* Peak tailing occurred and samples were not quantified. 
** Only one sample tested. 
*** Values were not determined. 
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All samples were filtered through Whatman No. 3 glass fibre filters to remove 
suspended solids. The samples were then syringe filtered through 0.2µm nylon 
filters into glass amber HPLC vials. These were then analysed by LC-MS with 
the combined parameters (see Table 2.3). Famotidine was detected in each 
case. The presence of TPN was not as abundant in either tank and SPE was 
conducted on the samples to concentrate the analyte prior to LC-MS analysis. 
When analysing for TPN only, the optimised parameters for TPN were used 
(see Table 3.2). The samples were concentrated by a factor of 25 which gave 
responses of between 0.15mg/L to 22mg/L in WWC1. The percentage recovery 
of TPN through the SPE cartridges is 93% ± 4%. When the concentration factor 
and percentage recovery was taken into account, the measured values of TPN 
were between 0.007mg/L and 0.96mg/L (see Table 4.1). On five occasions, the 
quantity of TPN was not determined in the pH adjust tank (see Table 4.1). For 
two of these (7th Aug and 3rd Sep) peak tailing occurred during the 
chromatography stage of analysis and the concentration of TPN was not 
determined. On the other occasions (5th Aug, 14th Aug and 16th Sep) TPN was 
detected but their concentrations were below the limit of quantitation 
(0.016mgL) 
 
In all cases except one, the concentration of famotidine was higher in WWC1 
than in the pH adjust tank (see Figure 4.1). The model predicted that this 
would occur for each permutation (as described in section 4.4). The actual 
concentrations of famotidine (0.8mg/L to 16.6mg/L) are considerably below 
those modelled (0.879g/L and 0.954g/L). This may be explained on the grounds 
that other processes feed into both WWC1 and pH adjust tank. The 
wastewater from another pharmaceutical produced on-site is also transferred 
into the pH adjust tank. In addition water from the boiler house and cooling 
towers is pumped into WWC1 on a daily basis.  
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Figure 4.1 Timeline of famotidine sampling results in WWC1 (blue) and the pH 
adjust tank (pink). 
 
 It is not known what volumes of water are transferred to WWC1 and the pH 
adjust tank. Lower concentrations of TPN than famotidine were reported 
(0.007mg/L and 0.96mg/L) in WWC1 (see Table 4.1) in all samples. This was 
predicted by the model because the quantity of famotidine present in VE-
2300/2800 is much larger than TPN (approximately 26 times) and therefore a 
larger quantity of famotidine is likely to be transferred to the wastewater 
treatment plant. In all but four cases (12th August, 19th August, 26th August and 
the 2nd September), TPN was found to be in a higher concentration in WWC1 
than in the pH adjust tank. This is contrary to what is predicted in the model, in 
which TPN was shown to have higher concentrations in the pH adjust tank. This 
anomaly may be explained by a higher dilution factor of TPN by other water 
entering the pH adjust tank.  
 
The left hand columns of Table 4.2 outline a timeline of the water tank washes 
which are transferred to WWC1. The estimated quantity of both famotidine 
and TPN in WWC1 are shown in the green columns. These predictions are 
based on the assumption that WWC1 is full and has a capacity of 100m3. Such 
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estimates were not possible for the pH adjust tank but show the 
concentrations of famotidine and TPN on each sample day. 
 
The WWC1 tank automatically empties when it reaches a point. This occurs 
continuously, emptying several times per week. As the tank emptied 
automatically, it was difficult to know what volume of wastewater was in 
WWC1 when sampling the tank. The process washes could not be linked to the 
concentrations of TPN and famotidine in WWC1. A sampling point after each of 
the washes and centrifuges would be beneficial in monitoring concentrations 
of the analytes rather than measuring the concentrations in wastewater tanks. 
The lost quantities of both famotidine and TPN from the process could not be 
back calculated as a result of this. Ideally, one would sample at each of the 
centrifuges to obtain accurate data regarding the composition of the filtrate. 
The closest point to obtain samples of filtrate is at the pH adjust tank, which is 
after solvent recovery. 
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4.2 SuperPro Designer v5.0 
 
SuperPro Designer V 5.1® from Intelligen, Boston, MA, USA was used to 
model the production of famotidine. This software is used to model chemical 
processes and monitor their performance. It allows the user to select various 
unit operations, such as reaction vessels, distillation columns, 
chromatography columns, centrifuges etc. Specific data about a process can 
be inputted, for example, chemical reactions, reaction extents, quantity of 
by-products created and crystallisation efficiency. SuperPro Designer was 
used to model the production of famotidine and to estimate quantities of 
impurities produced. Specifically, the reaction extent and completions were 
varied in a series of modelling steps in order to elucidate what quantity of 
raw material is unreacted or converted to impurities, and what quantity of 
intermediates is produced. Two production batches were studied (7th April 
2008 and 4th August 2009) and data taken on site during these processes 
were used to create the SuperPro Designer model. These data were 
compared with average values of previous production batches and showed 
no significant deviation. 
 
Various assumptions were made in order to provide a closely fitting model 
with the real process. Assumptions can also eliminate unnecessary 
calculations and by omitting data which were far outside the likely range, the 
calculations were more focussed.  The SuperPro Designer model created was 
split into four parts: imidate production (see Figure 3.1), crude famotidine 
production (see Figure 3.4), semi-pure famotidine purification (see Figure 
3.6) and final pure famotidine (see Figure 3.7). The two sampling points at 
the Astellas facility are at WWC1 and the pH adjust tank (see Figure 4.2).  
 
The assumptions which influenced the model outputs to the greatest degree 
were: (i) the purity of TPN (97% - 100%), (ii) the conversion of TPN to imidate 
(90% - 95%) and (iii) the conversion of imidate to crude famotidine (76% - 
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78%). Assumptions which fit the average production batch best are shown in 
Appendix B. The model works well in predicting the percentage composition 
of solvents in waste streams (Ettarh, 2008) (see Appendix G). From the 
information provided by Astellas, the model showed a reasonably good 
relationship with the quantity of product predicted to be produced and 
product lost to waste streams. More information is required however, 
regarding aspects of the other processes on site, and by how much they are 
diluting the compounds of interest in waste streams. Up to 12.84kg of 
famotidine are predicted to be lost during the purification process.  
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pH Adjust
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Recycled Sulphamide
Sample point 1
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Figure 4.2 Wastewater streams of the production process which displays the 
sampling points. 
 
In the first step in the process, the intermediate imidate is produced. A range 
of values for the purity of TPN, the quantity of imidate formed, the amount of 
impurities produced and the amount of material which is retained in the first 
centrifuge, MA-2200 was investigated using baseline data obtained from 
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Astellas. The baseline data indicate that during this process, 455kg of imidate 
with 95% purity are produced. Therefore any predicted value outside the 
range of 450kg – 460kg was rejected from the model. Using SuperPro 
designer, VE-2200 was programmed to retain 0.1% of the total volume of the 
mother liquor. This would simulate residue adhering to the walls of the tank. 
The tank was then washed with 127L water and transferred to WWC1. The 
values used for components in three of the streams in the model were 
monitored: the filtrate to WWA (WWA-101), the retentate continuing with 
the batch (S-103) and the 127L water wash of VE-2200 (WWC-101). Any 
calculated values that lay outside the range of 420kg – 430kg of pure imidate 
observed in Astellas were discarded. 25kg of impure imidate are impurities or 
unreacted TPN and the weights of each are accounted for in the model. 
SuperPro calculates the composition of each stream and presents data in 
tabular format. An example of stream composition is shown in Table 4.3.  
Table 4.3 Composition of stream S-103 following centrifugation in MA-2200. 
Component 
Flowrate 
(kg/batch) 
Mass Composition 
(%) 
Conc. (g/L) 
A-2 0.45 0.09 0.99 
A-3 4.24 0.85 9.39 
A-4 4.49 0.90 9.93 
A-5 3.99 0.80 8.82 
Imidate 428.58 85.60 948.65 
Methanol 45.67 9.12 101.08 
TPN 13.29 2.65 29.42 
 
This example is based on the assumptions that: (i) TPN is 99% pure (415.8kg 
TPN and 4.2kg A-5), (ii) the reaction between TPN and methanol is 92% and 
(iii) 99% of imidate is in the retentate (S-103) post centrifugation. One 
percent of imidate is assumed to be lost in the centrifugation process and is 
transferred to stream WWA-101 (see Table 4.4). 
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Table 4.4 Wastewater stream WWA-101 post centrifugation in MA-2200.  
Component Flowrate 
(kg/batch) 
Mass 
Composition 
(%) 
Conc. (g/L) 
A-2 8.51 0.07 0.72 
A-3 0.22 0.00 0.02 
A-4 0.24 0.00 0.02 
A-5 0.21 0.00 0.02 
Ammonia 0.88 0.01 0.07 
Carbon dioxide 64.87 0.53 5.47 
Dioxane(1,4) 879.49 7.20 74.17 
Imidate 4.33 0.04 0.37 
Potassium chloride 337.82 2.76 28.49 
Methanol 291.18 2.38 24.56 
Potassium carbonate 1088.47 8.91 91.80 
TPN 3.32 0.03 0.28 
Water 9542.68 78.08 804.78 
 
4.3.1 SuperPro Designer modelling of imidate production 
 
The impurity A-5 is known to be present in TPN and therefore the purity of 
TPN was included as a variable. The purity of the raw material is an important 
factor in analysing the overall process. With purity below 100%, the model 
becomes more complicated due to the presence of impurity A-5. Preliminary 
values for purity of TPN ranged from 70% - 100%. Further information from 
Astellas revealed that the range in purity was between 97.5% and 100% for 
TPN. A-3 and A-4 are known to form during the reaction of TPN and methanol 
and are found in impure imidate. However it was not known what quantity of 
either impurity was in impure imidate.  
 
By analysing the data at this stage in the process, important assumptions in 
the imidate production stage could be verified. The TPN purity is thought to 
be between 97% and 100% with a reaction extent of between 90% and 95%.  
The purity of imidate after MA-2200 is usually 95%. The 5% impurities are 
made up by unreacted TPN and small quantities of A-3, A-4 and A-5. 
Unreacted TPN reacts with water to form A-3. As water is abundant at this 
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stage in the process (6947L), it was assumed that 50% of TPN would react 
with water to create A-3. A-3 reacts with water to form A-2, an inorganic 
compound. It was assumed that the conversion rate of A-3 to A-2 was 50% 
and a further 25% was assumed to be converted to A-4. The quantities of 
these impurities, along with that of unreacted TPN were important when 
considering the efficiency of the process.  
 
The dry weight of imidate was modelled to be between 450kg and 460kg. 
Routine HPLC analysis in Astellas indicates that the purity of dry imidate is 
95%, thus approximately 25 kg of imidate are impurities. Modelling revealed 
that the purity of TPN was between 97% and 100% and the conversion rates 
of imidate production were between 90% and 95% (see Table 4.5). Therefore 
the quantity of pure imidate produced was modelled to be between 420kg 
and 430kg. All values which predicted the dry weight of impure imidate to be 
outside the range of 450kg – 460kg were discarded. Of these valid 
predictions, those which predicted pure imidate to be outside the range 
420kg – 430kg were also discarded.  
Table 4.5 The values used for the assumptions made to model Step 1 using 
SuperPro Designer. 
Assumption Investigated values (%) Values modelled (%) 
TPN purity 70  - 100 97 - 100 
Reaction completion 70  - 100 90 - 100 
TPN in retentate  0, 70, 80, 90, 99, 100 80 
Imidate in retentate 99  and 100 99 and 100 
 
Once imidate is produced in VE-2200, it is transferred to a centrifuge, MA-
2200. Ninety five percent of A-2 was assumed to be washed away in the 
filtrate, WWA-101, as it is an inorganic compound. All other inorganic 
compounds were assumed to be removed to the filtrate. Twelve 
permutations regarding the fate of TPN and A-5 in the centrifuge were 
examined. These were investigated as it is currently unknown what fate 
these compounds have in the centrifuge (i.e. whether either compound is 
removed in the filtrate or remains in the retentate). 80% retention of TPN 
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keeps the quantity of impure imidate between 450kg and 460kg, whereas 
higher retention rates of TPN result in quantities of impure imidate above the 
accepted range. TPN is highly insoluble in water and has large crystal size, 
(see Figure 1.3) which would lead to the assumption that unreacted TPN 
remains with impure imidate. All unreacted TPN is assumed to be present 
with A-5 the impure imidate.  
 
Eighty eight data points were generated and this number had to be reduced. 
Any data points generated which predicted TPN purity to be lower than 97% 
were discarded. Elimination of the irrelevant data points was necessary in 
order to manage the data. The data which were within the range and were 
consistent with the assumptions are presented in Table 4.6. This represents 
permutations of the aggregate masses of TPN, imidate and impurities (A-2 to 
A-5), all of which are between 450kg and 460kg 
 
Stream S-103 contains imidate (see Table 4.3), which accounts for 94.1% of 
the solid material in the stream. The remaining 5.9% of solid material 
comprises impurities (A-2, A-3, A-4 and A-5) and unreacted TPN. Values 
examined for the retention of TPN post centrifugation were 100%, 99%, 90%, 
80%, 70% and 0%. The actual conversion of TPN to impure imidate (94 % - 96 
% pure) is approximately 95% and an assumed retention of 80% of TPN 
corresponds to the actual value of impure imidate. Sixty seven permutations 
of impure imidate were modelled generating values between 450kg and 
460kg. These data were further reduced to 30 points, as only crude imidate 
with a quantity of pure imidate which was between 420kg – 430kg was kept. 
These values were brought forward to the next stage for further analysis. The 
subsequent washes of VE-2200 were recorded and are included in the mass 
balance for WWC1. 
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Table 4.6 Process inputs for imidate formation and post MA-2200 stream 
components  
Assumptions modelled Process stream S-103 components (kg) post MA-2200 
TPN 
purity 
(%) 
Reaction 
Completion 
(%). 
Imidate in 
retentate 
(%) 
A-2  A-3 A-4 A-5 Imidate TPN 
Total 
impure 
imidate 
100 91 99 0.51 4.82 5.10 0.00 428.20 15.26 453.88 
100 91 99 0.51 4.82 5.10 0.00 428.20 15.10 453.73 
100 90 100 0.57 5.35 5.66 0.00 427.77 16.95 456.31 
100 90 100 0.57 5.35 5.66 0.00 427.77 16.78 456.14 
100 90 99 0.57 5.35 5.66 0.00 423.49 16.95 452.03 
100 90 99 0.57 5.35 5.66 0.00 423.49 16.78 451.86 
99 92 99 0.45 4.24 4.49 3.99 428.58 13.43 455.16 
99 92 99 0.45 4.24 4.49 3.99 428.58 13.29 455.03 
99 91 100 0.50 4.77 5.05 3.99 428.20 15.10 457.61 
99 91 100 0.50 4.77 5.05 3.99 428.20 14.95 457.46 
99 91 99 0.50 4.77 5.05 3.99 423.92 15.10 453.33 
99 91 99 0.50 4.77 5.05 3.99 423.92 14.95 453.18 
99 90 100 0.56 5.30 5.61 3.99 423.49 16.78 455.73 
99 90 100 0.56 5.30 5.61 3.99 423.49 16.62 455.57 
98 93 99 0.39 3.67 3.89 7.97 428.86 11.63 456.41 
98 93 99 0.39 3.67 3.89 7.97 428.86 11.51 456.29 
98 92 100 0.44 4.20 4.44 7.97 428.53 13.29 458.88 
98 92 100 0.44 4.20 4.44 7.97 428.53 13.16 458.75 
98 92 99 0.44 4.20 4.44 7.97 424.25 13.29 454.59 
98 91 100 0.50 4.72 5.00 7.97 423.87 14.95 457.02 
98 91 100 0.50 4.72 5.00 7.97 423.87 14.80 456.87 
97 95 99 0.27 2.60 2.75 11.96 433.61 8.22 459.41 
97 95 99 0.27 2.60 2.75 11.96 433.61 8.14 459.33 
97 94 99 0.33 3.12 3.30 11.96 429.05 9.87 457.61 
97 94 99 0.33 3.12 3.30 11.96 429.05 9.77 457.52 
97 93 100 0.38 3.64 3.85 11.96 428.77 11.40 459.99 
97 93 99 0.38 3.64 3.85 11.96 424.48 11.51 455.82 
97 93 99 0.38 3.64 3.85 11.96 424.48 11.40 455.70 
97 92 100 0.44 4.16 4.40 11.96 424.16 13.16 458.26 
97 92 100 0.44 4.16 4.40 11.96 424.16 13.02 458.13 
 
 
The left hand side of the Table 4.6 (columns 1 to 3) displays the assumptions 
modelled with all permutations. The corresponding outputs of these 
assumptions are listed on the right hand side of the table (columns 4 to 9). 
The aggregate dry weight of impure imidate is presented in column 10. The 
methanol component of S-103 is omitted from the table as only the dry value 
is of interest. The total impure imidate aggregate values shown are within the 
range of 450kg and 460kg. 
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The quantity of pure TPN is inversely related to the quantity of A-5 – the 
impurity commonly found in TPN. It was assumed that A-5 was inert and 
proceeded through the process unreacted and 95% remained in the 
retentate following the first centrifuge, MA-2200. Unreacted TPN and A-5, 
along with other impurities, A-2, A-3 and A-4 contribute to the weight of 
impure imidate post-centrifugation, and this has been accounted for in the 
model (see Table 4.6).   
4.3.2 SuperPro Designer modelling of TPN fate in WWC1 
 
The quantities of TPN lost to WWC1 are predicted to range from 0.014 kg to 
0.021kg. The 127L water washes of VE-2200 and subsequent discharge to 
WWC-101 are the only routes whereby TPN enters WWC1 (see Figure 1.4). 
Neither of the other water washes (streams WWC-102 and WWC-103) which 
feed into WWC1 contains traces of TPN. A much larger amount of TPN is 
discharged to WWA-101 in the cake washes of MA-2200 and MA-2300/2800. 
The very low concentrations of TPN predicted to be in WWC1 (0.022g/L – 
0.032g/L) are approximately a factor of 100 more than those in actual 
samples. This is similar in magnitude to the differences between the model 
predictions for famotidine concentration in WWC1 and the experimental 
data.  
 
The water which is used to wash tank VE-2200 (see Figure 3.1) is transferred 
to holding tank WWC1 where actual water samples were taken (see Figure 
1.4). It is predicted by the model that between 0.01kg and 0.02kg of TPN is 
transferred to WWC1. This accounts for 0.1% of unreacted TPN in VE-2200. 
WWC1 is used as a tank wash receiver at two times throughout the process, 
but only this stage is predicted to contribute to the presence of TPN in 
WWC1. Samples were taken immediately after a two week shut down of the 
plant. It was expected that there would be zero quantities of TPN in the 
samples. However, residual quantities of TPN were recorded (see Table 4.1). 
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Based on an estimated tank size of 100m3, this equates to a mass of 44g of 
TPN.  
 
4.3.3 SuperPro Designer modelling of TPN fate in WWA 
 
The quantities of TPN which are removed in the centrifuge MA-2200 to 
stream WWA-101 are predicted to be between 2.878kg and 4.196kg (see 
Table 4.1). The filtrate (WWA-103) from centrifuge MA-2400 is estimated to 
contain between 0.115kg and 0.168kg TPN and is stored in WWA. The model 
predicts that the aqueous fraction of WWA represents 65% of the total 
18775L per batch. The liquid from WWA is distilled and the distillate is 
transferred for thermal treatment and the aqueous fraction is sent to the pH 
adjust tank.  The pH adjust tank contains the condensate from the solvent 
recovery and the contents from WWC1. The predicted quantities of TPN in 
the pH adjust tank (3.008kg – 4.384kg) are much greater than those in WWC1 
(0.014kg – 0.021kg).  
 
The water volume of WWC1 (627L) is much lower than the volume of 
condensate from the solvent recovery step (13,840L) which means the 
concentrations of TPN predicted in WWC1 (0.022g/L – 0.032g/L) and pH 
adjust (0.085g/L – 0.122g/L) are of the same order of magnitude. 
Approximately 73% of the unused TPN (up to 16.59 kg per batch) is predicted 
by the model to then go to thermal treatment. 
4.4 SuperPro Designer modelling of crude famotidine production  
 
The reaction of imidate and sulphamide creates famotidine. From batch 
studies and information provided by Astellas it is known that yield of crude 
famotidine is approximately 74%. This does not take into account the 
impurities that are transferred from MA-2200 (A-3, A-4 and A-5) or any 
unreacted TPN. Other impurities are formed during the reaction between 
imidate and sulphamide. Impurities A-7 and A-8 are formed at this point in 
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the process. The percentage of A-8 present in crude famotidine determines 
the amount of activated carbon used to purify the crude famotidine at a later 
step. From information received from Astellas, A-7 is unstable, and is 
converted to A-8. However, programming SuperPro to perform this reaction 
proved difficult, and an alternative reaction was made. 0.1% of famotidine 
reacts with imidate in a 1:1 ratio, to produce an equimolar quantity of A-8, 
ammonia and methanol. This equates to about 0.06% to 0.07% of the yield of 
crude famotidine. These quantities of impurities had to be taken into account 
and were included in the permutations investigated. The purity of crude 
famotidine is usually 95% and for the model a range of 91% - 96% was 
examined. The dry weight of crude famotidine is approximately 413kg. The 
range of crude famotidine accepted for the model was between 405kg and 
420kg. The conversion rate of imidate and sulphamide to crude famotidine 
was initially modelled between 10% and 100%. The assumptions made are 
shown in Table 4.7. Impurities that are found at Astellas at this stage are A-7 
and A-8.  
 
Table 4.7 Values used for the assumptions made to model the production of 
crude famotidine using SuperPro Designer. 
Assumption Preliminary values Values modelled 
Reaction Completion 10% - 100%, 70% - 80% 
Crystallisation  94%, 96%, 98%, 99% and 100% 99% 
 
All values outside 70% and 80% were far from those observed in Astellas and 
were discarded. The range of 70% to 80% was narrowed further to between 
74% and 78%. After the reaction, the reactor is seeded with A-form crystals. 
It is assumed that the efficiency of crystallisation is 99% and that some of the 
impurities are also crystallised. It is assumed that only 1% of the unreacted 
imidate remains with the crude famotidine. The permutations of this step 
reveal that the quantities of unreacted imidate ranged from 92.54kg and 
110.845kg, a majority of which is eventually transferred for thermal 
treatment. The reaction of imidate and sulphamide in VE-2800 has a low 
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yield, typically 74%, and it is at this stage that most of the losses of product 
occur. The reason the yield is low (74%) can be ascribed to two possibilities: 
either the breakdown of imidate to impurities A-7 and A-8, or imidate is 
unreacted and is eluted in the filtrate. In either case, there is a large quantity 
of material in excess of 100kg per batch being sent to the sulphamide 
recovery facility. At the recovery step, the distillate is not used any further in 
the process, and is transferred to WWA1 for thermal treatment. It would be 
of interest to sample the composition of the waste stream at this point, but 
there is no sampling point here. 
 
4.4.1 SuperPro Designer modelling of famotidine fate in WWC1 
 
The largest loss is predicted to occur during centrifugation at MA-2600/4600. 
Famotidine is first produced in VE-2300 when imidate reacts with 
sulphamide. After this reaction the first water wash of a reactor which is 
transferred to WWC1 happens in VE-2500. At this point famotidine has been 
dissolved in water, ethanol and acetic acid. Powdered activated carbon is 
added to remove impurities. It is assumed that 0.1% of the tank contents 
adhere to its walls which is then washed with 500L of water which goes to 
WWC1 via stream WWC-101. Between 0.384kg and 0.405kg of famotidine 
are lost at this point. The dissolved famotidine and powdered activated 
carbon are passed into a bag filter where the product is in the filtrate. 
Although the purpose of this process is to remove impurities, it is assumed 
that famotidine is also adsorbed.  
 
Research investigating the properties of various activated carbons is being 
carried out in the School of Biotechnology in DCU. A preliminary study of the 
powdered activated carbon used by Astellas indicates high adsorptive 
properties. Isotherms investigating adsorption of famotidine with 
concentrations of 0-50mg/L in 50mL of water (pH4) with 0.1g of activated 
carbon were performed. In all instances the famotidine was completely 
removed. From these experiments the activated carbon is calculated to have 
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a maximum adsorbance capacity for famotidine of approximately 110mg/g. 
Astellas use between 7kg and 30kg of activated carbon per batch and an 
average of 18kg was used for the model.  It is assumed that 0.5% of dissolved 
famotidine is adsorbed and removed from the mother liquor. Up to 2.201kg 
of famotidine are predicted to be removed from the process stream. The 
carbon is rinsed with water and packaged for off-site incineration. Ten 
percent of the famotidine is assumed to be removed during rinsing and the 
rinse water passes eventually into WWC1. This 10% loss of famotidine has 
been included in each modelled batch. However the volume of water is 
unknown and not included in the model. 
 
As is the case with TPN, more famotidine (10.094kg) is predicted by the 
model to be present in the condensate of the solvent recovery stage than the 
quantity in WWC1 (0.625kg). The concentrations predicted to be in the pH 
adjust tank and WWC1 were 0.332g/L - 0.35g/L and 0.879g/L - 0.954g/L, 
respectively. In this case, the wastewater from WWA dilutes the famotidine 
to a lower concentration than what is estimated to be present in WWC1. 
4.4.2 SuperPro Designer modelling of famotidine fate in WWA 
 
Quantities of famotidine which were predicted to be in WWA are lost by 
means of cake washing in centrifuges MA-2400 and MA-2600/4600. MA-2400 
separates B-form famotidine crystals from the process stream and the cake is 
washed with water (14 cycles of 75L/cycle) into waste stream WWA-103 (see 
Figure 3.6). Up to 4.224kg of famotidine are predicted to be lost.  In the last 
centrifuge of the process (MA-2600/4600) as much as 6.013kg are estimated 
to be washed into the filtrate (WWA-104) (see Figure 3.7). As mentioned 
above, the contents of WWA undergo solvent recovery. The quantities of 
famotidine in the condensate range from 9.58kg to 10.09kg.  
 
4.5 Sulphamide recovery 
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Following centrifugation in MA-2300, the filtrate is processed to recover 
sulphamide and recycle it back into VE-2300. The filtrate of MA-2300 is 
distilled and the condensate is centrifuged in MA-2900. The unreacted 
imidate is not assumed to have crystallised in the seeding process of VE-
2300/2800 and therefore remained dissolved. The cake is washed with 
methanol and the model predicts that up to 145kg of sulphamide are 
recycled. Only 4kg of famotidine are lost to thermal treatment which is in 
contrast to TPN where up to 20.77kg are lost to this treatment. 
 
The SuperPro designer model predicts a larger amount of famotidine than 
TPN present in WWC1. This is observed in the actual process in all cases of 
sampling. The quantity of famotidine produced is approximately 26 times 
that of unreacted TPN available. Therefore it is reasonable to assume that 
more famotidine than TPN will be lost. The actual wastewater analysis 
indicates low concentrations of both analytes but when one considers that 
the capacity of WWC1 is approximately 320m3, significant quantities of each 
analyte are involved. In a homogenous mixture this could equate to up to 
1.653kg of famotidine on the 2nd September, and up to 0.044kg TPN on the 
19th August. WWC1 does not only store water from the famotidine process. 
More water is used by the boiler house and cooling towers. This contributes 
to a dilution factor of both analytes. An investigation into water usage in 
Astellas was carried out in 2005 which noted that the famotidine process 
uses 118m3 industrial water per week equalling 6.7% of the overall 
consumption (Brookes and Duffy, 2005). The model predicts approximately a 
2kg loss of famotidine following a wash down of VE-2500.  
 
As the model accurately predicts the relative quantities of both TPN and 
famotidine in wastewater streams, then some credence can be given to the 
predicted quantities of other components in the process.  For example, the 
quantity of the intermediate compound imidate, which reacts with 
sulphamide to form famotidine, is predicted to be in excess of 100kg after 
this step. This is one of the most abundant non-solvents in the process, after 
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famotidine, sodium acetate and potassium chloride. This may be of 
importance to Astellas as it may be possible to recycle it, thereby reducing 
costs. It may also be of significance when one considers the possibility of the 
introduction of more stringent regulations in the Water Framework Directive.   
 
The contents of WWC1 are transferred to the second sampling point, the pH 
adjust tank. Other process waters are also transferred to this tank, which in 
turn are expected to dilute both analytes. This is the case for famotidine as all 
concentrations analysed are lower in this tank. TPN generally has a lower 
concentration in the pH adjust tank, except for the samples taken on the 26th 
August and the 10th September. On these occasions there was a large 
difference in sample responses using LC-MS (see Appendix F). The 
corresponding WWC1 sample was not tested in duplicate on the 26th August 
and for WWC1 on the 10 September the sample responses differed hugely 
(22475 and 8413, see Appendix F). Therefore these results may not be 
accurate. When analysing TPN from the pH adjust tank the extracted ion 
chromatogram of TPN showed tailing factor of more than 1.5 in some 
instances. This is likely due to the matrix of the sample. This phenomenon did 
not occur in the samples from WWC1. As the pH adjust tank is fed by another 
pharmaceutical process, it is assumed that this caused the TPN peak to tail. 
The pH adjust sampling point operates by overflowing into a lagoon. It does 
not get emptied and remains at the same level all of the time. No data was 
available to determine either the inflow or outflow of wastewater in the 
system. Therefore a mass balance of this point was not possible. 
 
4.6 Model Steps 3 and 4 - Purification of famotidine 
 
Data from the crude famotidine production step were brought forward to the 
purification stage. The assumption that there was a loss of product in the 
crystalliser VE-2400 was investigated. Crystallisation efficiency values of 94%, 
96%, 98%, 99% and 100% were input into SuperPro. As there was only one 
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assumption at this stage of the model, it was coupled with those of step 4: 
adsorption of material to activated carbon in VE-2500, and crystallisation of 
pure famotidine in VE-2600/4600.  
 
Efficiency values for both crystallisation steps were assumed to be between 
94% and 100%. The amount of semi-pure famotidine (SPFM) removed by 
adsorption to activated carbon was examined. The role of the activated 
carbon is to remove residual impurities from the SPFM. These impurities have 
similar structures to the final product so it is likely that pure famotidine is 
also adsorbed and removed from the process. The values examined are 
shown in Table 4.8. 
Table 4.8 Values used for the assumptions made to model the purification of 
famotidine using SuperPro Designer. 
Assumption Percentages Investigated 
Crystallisation in VE-2400 95%, 96%, 97%, 98%, 99%, 100% 
Activated carbon removal of SPFM  0.1 %, 0.5% and 1% 
Crystallisation in VE-4600 95%, 96%, 97%, 98%, 99%, 100% 
 
 
The average quantity of pure famotidine recovered by Astellas is 385kg. A 
range of 375kg to 395kg was applied to the model. Any value outside this was 
not considered. From these acceptable data, it was elucidated that the 
crystallisation that occurs in each of the reactors VE-2400 and VE-4600 was 
between 98% and 100%.  
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Chapter 5 
Conclusions 
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5.1 Conclusions 
 
There was no sample point for wastewater closer to the process than WWC1. 
A model was constructed using information regarding the famotidine 
production process and in consultation with key personnel from Astellas. No 
concentrations of impurities, intermediates, raw materials or products in 
wastewater streams in the plant had previously been monitored. The 
SuperPro Designer model follows the production protocols set out by 
Astellas, whose product yield is approximately 65% or 385kg of famotidine 
from 420kg TPN. The model examined various permutations of processing 
parameters which predicted yields of between 376.6kg and 395.5kg.  
 
The presence of impurities makes modelling difficult as their weights had to 
be accounted for. The large quantity of data generated meant that not all 
permutations could be examined. SuperPro Designer is not able to be trained 
and iterations of each permutation are required to get meaningful data.  
 
SuperPro Designer is used as a scheduling tool by many industries and allows 
for the same reactors to be used for different stages in the process. In 
Astellas however, each reactor has a single purpose which made modelling 
easier. Problems arose when a crossover between batch and continuous 
processes were merged. Sulphamide is recovered by Astellas and added to 
new sulphamide in each batch. However, this was not possible to model 
using SuperPro as the initial quantity of sulphamide (349.9kg) was being 
added to the recovered quantity (140kg) and each iteration increased the 
quantity of sulphamide in the reactor. The recovery of sulphamide was 
consequently omitted from the SuperPro Designer model. 
 
SuperPro has been used in this instance to identify points in the process 
where losses occur. It has been somewhat successful in identifying the 
centrifuges as major points of loss. Once this has been achieved, further 
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modelling may be carried out using other software. For instance, 
computational fluid dynamics may be used to examine individual fluid flows 
in each of the unit operations and may provide more information than the 
overview provided by SuperPro. 
 
5.2 Reasons for losses 
 
Poor conversion rates from imidate to famotidine have been identified by the 
model as causing significant reductions in product formation. This is evident 
from the large amount of unreacted imidate present following the 
crystallisation of crude famotidine. Between 22% and 26% of imidate is 
predicted by the model to remain unreacted in VE-2300/2800. Further 
quantities of product are predicted to be lost as a result of the reactions in 
this reactor. The crystallisation step dictates that 99% of the pure famotidine 
present crystallises out of solution. Several problems have been encountered 
using crystallisation in the pharmaceutical industry and these are: (i) the 
control of supersaturation and particle size distribution, (ii) effective use of 
seed, (iii) efficient measurement of solubility’s in multiple solvent systems to 
maximise purification and yield and (iv) the identification and retention of the 
most stable polymorphic form purification and yield (Kirwin and Orella, 
2002). Precipitation of famotidine occurs when the cooled batch is seeded 
with pure famotidine crystals. Significant losses are incurred during 
centrifugation as dissolved famotidine is washed away in the centrifuges. 
Improved crystallisation will have a positive impact on the overall purity and 
yield of famotidine. Inadequate cooling periods for crystal generation will 
inhibit crystal formation and dissolved product will be washed into waste 
streams post centrifugation. However, energy balances were not considered 
for this thesis. Further analysis into the energy balances within the plant may 
highlight inadequacies in the process.  
 
 
 67 
5.3 Concluding remarks 
 
To verify the validity of the model, a sampling regime was organised with 
Astellas following a two week shutdown of the plant. It was envisioned that 
this period would allow residual pharmaceuticals to pass through the 
wastewater treatment facility. It was expected that a correlation between 
the quantity of analytes present and an increase in production would be 
observed. This did not occur. Instead, a peak in levels of both TPN and 
famotidine occurred in the fourth week of sampling. This is of significant 
importance to Astellas as it may equate to losses of 0.43% of product, or 
1.635kg. Further analysis of the relevant process streams should be carried 
out in order to elucidate what is causing these losses. It is not only important 
from an economical viewpoint but as an environmental concern. 
Unaccounted losses of any chemicals in a pharmaceutical plant may have 
serious consequences to the renewal of environmental licences. Future work 
should entail mass flow analysis of the other pharmaceutical processes on-
site along with water balances of all processes to narrow margins of error 
while modelling. This could be of high value to Astellas as it may highlight the 
locations of losses of not only products but also intermediates and raw 
materials. More precise analytical techniques are continually contributing to 
the tightening of regulations and pharmaceutical companies must pay careful 
attention to these laws.  
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Appendix B 
 
Step 1 Assumptions which fit the average batch performance best 
Assumption Value 
TPN purity 99% 
TPN conversion to imidate 90% 
A-3 formation from unreacted TPN 50% 
A-2 formation from A-3 50% 
A-4 formation from A-3 25% 
Adherence to tank wall VE-2200  0.1% 
Imidate retention in MA-2200  100% 
TPN retention in MA-2200  80% 
A-2 Retention in MA-2200 5% 
A-3 Retention in MA-2200 95% 
A-4 Retention in MA-2200 95% 
A-5 Retention in MA-2200 95% 
 
 
Step 2 Assumptions which fit the average batch performance best 
Assumption Value 
Imidate conversion to CFM  76%  
Crystallisation of CFM  99% 
A-6 formation (A-3 + sulphamide) 10% 
A-1 formation (A-2 + sulphamide) 80% 
A-8 formation (famotidine + imidate) 0.1% 
Imidate degradation to A-4  (water is rate limiting factor) 80% 
A-1 retained in MA-2300/2800 10% 
A-2 retained in MA-2300/2800 0% 
A-3 retained in MA-2300/2800 10% 
A-4 retained in MA-2300/2800 10% 
A-5 retained in MA-2300/2800 10% 
A-6 retained in MA-2300/2800 10% 
 83 
A-7 retained in MA-2300/2800 10% 
A-8 retained in MA-2300/2800 10% 
 
Step 3 Assumptions which fit the average batch performance best 
Assumption Value 
Adherence to tank wall in VE-2400 0.1% 
Crystallisation of famotidine in VE2400  99% 
Adherence to tank wall in VE-2500 0.1% 
Adsorption of famotidine to carbon  0.5% 
 
Step 4 Assumptions which fit the average batch performance best 
Assumption Value 
Crystallisation of famotidine in VE-2600/4600  100% 
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Appendix E Properties of the compounds used to produce famotidine. 
 
Compound Molecular 
Wt. 
Density 
g/cm
3
 
Melting Pt. 
(˚C) 
Boiling Pt. 
(˚C) 
TPN 241.3 - 127-132 - 
Sulphamide 96.11 - 89-93 - 
Imidate 273.33 - 125-135 - 
Famotidine 337.43 - 164 - 
HCl gas 36.5 - - - 
Dioxane 88.1 1.0329 11. 101 
Methanol 32.04 0.7915 -97.8 64.7 
Potassium Carbonate 138.2 - - - 
Triethylamine 101.19 0.9445 114.7 89.3 
N,N, 
Dimethylformamide  
73.09 0.798 -61 153 
Ethanol 46.07 1.07 -117.3 78.5 
80% Acetic Acid - - -8 - 
NaOH pellet 40 - - - 
Aq NaOH 25% - 1.27 -17 - 
Aq Sulphuric 35% - 1.26 -86 - 
Acetic Acid (glacial) 60.05 1.053 16.7 118 
Dioxane/Methanol (2:1) - 0.972 -7 - 
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Appendix F-i LC-MS responses of famotidine in the pH adjust tank. 
 
Date 
Sample A 
(259 m/z) 
Sampe B 
(259 m/z) 
Mean 
(259 m/z) St. Dev 
Conc. 
(mg/L) 
05-Aug 13588 13646 13617 41.01 1.1 
07-Aug 15284 15012 15148 192.33 1.23 
10-Aug 14150 14248 14199 69.3 1.15 
12-Aug 12226 11809 12018 294.86 0.97 
14-Aug 69671 6782 38227 44469.2 3.1 
19-Aug 16925 16279 16602 456.79 1.35 
21-Aug 5455 6550 6003 774.28 0.49 
26-Aug 11987 11629 11808 253.14 0.96 
28-Aug 3373 3300 3337 51.62 0.27 
01-Sep 51411 92771 72091 29245.9 5.85 
02-Sep 44405 41829 43117 1821.51 3.5 
03-Sep 69872 48252 59062 15287.7 4.79 
10-Sep 58823 60217 59520 985.71 4.83 
16-Sep 27889 27120 27505 543.77 2.23 
 
Appendix F-ii LC-MS responses of famotidine in WWC1. 
 
Date 
Sample A 
(259 m/z) 
Sample B 
(259 m/z) 
Mean  
(259 m/z) St. Dev 
Conc. 
(mg/L) 
05-Aug 33883 33882 33883 0.71 2.75 
07-Aug 8927 10850 9889 1359.77 0.8 
10-Aug 27584 25378 26481 1559.88 2.15 
12-Aug 46053 43532 44793 1782.62 3.63 
14-Aug 77257 69671 73464 5364.11 5.96 
19-Aug 24946 23927 24437 720.54 1.98 
21-Aug 9829 10484 10157 463.15 0.82 
26-Aug 17264 12288 14776 3518.56 1.2 
28-Aug - - - - - 
01-Sep - - - - - 
02-Sep 209749 197762 203756 8476.09 16.53 
03-Sep 132564 143178 137871 7505.23 11.19 
10-Sep 120999 127253 124126 4422.25 10.07 
16-Sep 68038 62828 65433 3684.03 5.31 
 
 
 
 
 
 
 
 89 
 
 
Appendix F-iii LC-MS responses of TPN in WWC1 after SPE. The 
concentration is calculated by the mean of the two samples the SPE 
concentration factor has been accounted for 
 
  155 155 mean stdev 
Conc. 
(mg/L) 
05-Aug 9212.00 8470.00 8841.00 524.67 0.041 
07-Aug 10788.00 11024.00 10906.00 166.88 0.066 
10-Aug 7568.00 8985.00 8276.50 1001.97 0.034 
12-Aug 30411.00 28164.00 29287.50 1588.87 0.286 
14-Aug 14462.00 14771.00 14616.50 218.50 0.110 
19-Aug 44821.00 39679.00 42250.00 3635.94 0.441 
21-Aug 15103.00 13927.00 14515.00 831.56 0.109 
26-Aug 40918.00 - 40918.00 - 0.425 
28-Aug - - - - - 
01-Sep - - - - - 
02-Sep 45550.00 29322.00 37436.00 11474.93 0.384 
03-Sep 2411.00 2363.00 2387.00 33.94 nq 
10-Sep 22475.00 8413.00 15444.00 9943.34 0.120 
16-Sep 2823.00 21727.00 12275.00 13367.15 0.082 
 
Appendix F-iv LC-MS responses of TPN in the pH adjust tank after SPE. 
The concentration is calculated by the mean of the two samples and the 
SPE concentration factor has been accounted for. 
 
  155 155 mean stdev 
Conc. 
(mg/L) 
05-Aug 3487.00 3962.00 3724.50 335.88 nq 
07-Aug - - - - 
peak 
tailing 
10-Aug 6952.00 6207.00 6579.50 526.79 0.014 
12-Aug 10208.00 10691.00 10449.50 341.53 0.060 
14-Aug 5006.00 5169.00 5087.50 115.26 -0.004 
19-Aug 9777.00 34650.00 22213.50 17587.87 0.201 
21-Aug 5702.00 6253.00 5977.50 389.62 0.007 
26-Aug 69636.00 102464.00 86050.00 23212.90 0.967 
28-Aug 82593.00 70765.00 76679.00 8363.66 0.854 
01-Sep 8155.00 7900.00 8027.50 180.31 0.031 
02-Sep 9423.00 9939.00 9681.00 364.87 0.051 
03-Sep - - - - - 
10-Sep 66876.00 47313.00 57094.50 13833.13 0.619 
16-Sep 644.00 2823.00 1733.50 1540.79 -0.044 
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Appendix G-i Comparison of the solvent composition in Astellas at the pH 
adjust tank and those in an example of the model (Ettarh, 2008). 
 
pH Adjust tank (Ettarh, 2008) SuperPro pH adjust tank 
Component % Composition Component % Composition 
Dimethylformamide 5.35 A-1 0.0028 
1,4 Dioxane 1.39 A-2 0.0524 
Ethanol 11.75 A-3 0.0268 
Ethylacetate  0.06 A-4 0.031 
Inorganic Residue 1.06 A-5 0.0256 
Methanol 1.09 A-6 0.0006 
Toluene  0.02 A-8 0.0013 
Triethylamine 0.01 Acetic-Acid 0.0005 
Water 81.71 Ammonia 0.0054 
Total 102.44 B-Form Famotidine Dissolved 0.0245 
  Carbon Dioxide 0.3995 
  Activated Carbon 0.1846 
  1,4 Dioxane 0.0595 
  Dissolved SPFM 0.0387 
  Dimethylformamide 0.0816 
  Ethanol 0.1448 
  Imidate 0.0293 
  KCl 2.0805 
  Methanol 0.0223 
  PFM 0.012 
  K2CO3 6.7034 
  Sodium Acetate 0.7451 
  Sodium Hydroxide 0.2611 
  TPN 0.0112 
  Triethylamine 0.002 
  Water 89.0535 
  Total 100.0 
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Appendix G-ii Comparison of the solvent composition in Astellas at 
WWC1 and those in an example of the model (Ettarh, 2008). 
 
Thermal Treatment (Ettarh, 2008) SuperPro Thermal Treatment 
Component % Composition Component % Composition 
Dimethylformamide 1.14 A-1 0.0001 
Ethanol  30.32 A-2 0.0013 
Ethylacetate 14.07 A-3 0.0001 
I,4 Dioxane  4.37 A-4 0.0001 
inorganic Residue  0.09 A-5 0.0001 
Methanol  31.27 A-6 0.0 
Toluene  11.37 A-8 0.0 
Triethylamine 1.28 Ammonia 0.0004 
Water  4.47 1,4 Dioxane 13.4294 
Total 98.38 Dissolved CFM 0.0593 
  Dimethylformamide 20.2618 
  Ethanol 33.6383 
  Imidate 1.4988 
  Methanol 25.4887 
  Sulphamide 1.4498 
  TPN 0.2281 
  Triethylamine 1.7872 
  Water 2.1564 
  Total 100.0 
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Appendix H-i Standard curve of famotidine (0 – 10mg/L) using LC-MS. 
y = 10626x + 19596
R
2
 = 0.9877
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Appendix H-ii Standard curve of TPN (0 – 10mg/L) using LC-MS 
y = 3597.7x + 5431.3
R
2
 = 0.9952
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